While progress is slow IMM is on to something.
IMP761 humanized IgG4 monoclonal antibody.
IMP761 has the potential to address the root cause of autoimmune diseases by specifically silencing the autoimmune memory T cells accumulating at the disease site which express LAG-3 as an exhaustion marker after being repeatedly stimulated with dominant self-peptides at the disease site. These findings were published in the Journal of Immunology in January 2020.
An IgG4 subclass monoclonal antibody may work better with IgG4 related diseases.
Immunoglobulin G4-related diseases (IgG4-RD) are chronic immune-mediated fibroinflammatory disorders.
Examples are autoimmune pancreatitis, retroperitoneal fibrosis and tubulointerstitial nephritis.
Big accomplishment for a small company.
Overnight Market report, page-189
-
- There are more pages in this discussion • 2,709 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |